Literature DB >> 18753132

DUSP6 (MKP3) null mice show enhanced ERK1/2 phosphorylation at baseline and increased myocyte proliferation in the heart affecting disease susceptibility.

Marjorie Maillet1, Nicole H Purcell, Michelle A Sargent, Allen J York, Orlando F Bueno, Jeffery D Molkentin.   

Abstract

The strength and duration of mitogen-activated protein kinase signaling is regulated through phosphorylation and dephosphorylation by dedicated dual-specificity kinases and phosphatases, respectively. Here we investigated the physiological role that extracellular signal-regulated kinases 1/2 (ERK1/2) dephosphorylation plays in vivo through targeted disruption of the gene encoding dual-specificity phosphatase 6 (Dusp6) in the mouse. Dusp6(-/-) mice, which were viable, fertile, and otherwise overtly normal, showed an increase in basal ERK1/2 phosphorylation in the heart, spleen, kidney, brain, and fibroblasts, but no change in ERK5, p38, or c-Jun N-terminal kinases activation. However, loss of Dusp6 did not increase or prolong ERK1/2 activation after stimulation, suggesting that its function is more dedicated to basal ERK1/2 signaling tone. In-depth analysis of the physiological effect associated with increased baseline ERK1/2 signaling was performed in cultured mouse embryonic fibroblasts (MEFs) and the heart. Interestingly, mice lacking Dusp6 had larger hearts at every age examined, which was associated with greater rates of myocyte proliferation during embryonic development and in the early postnatal period, resulting in cardiac hypercellularity. This increase in myocyte content in the heart was protective against decompensation and hypertrophic cardiomyopathy following long term pressure overload and myocardial infarction injury in adult mice. Dusp6(-/-) MEFs also showed reduced apoptosis rates compared with wild-type MEFs. These results demonstrate that ERK1/2 signaling is physiologically restrained by DUSP6 in coordinating cellular development and survival characteristics, directly impacting disease-responsiveness in adulthood.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18753132      PMCID: PMC2576531          DOI: 10.1074/jbc.M806085200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy.

Authors:  T Taigen; L J De Windt; H W Lim; J D Molkentin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

2.  Mechanistic basis for catalytic activation of mitogen-activated protein kinase phosphatase 3 by extracellular signal-regulated kinase.

Authors:  C C Fjeld; A E Rice; Y Kim; K R Gee; J M Denu
Journal:  J Biol Chem       Date:  2000-03-10       Impact factor: 5.157

3.  Mapping ERK2-MKP3 binding interfaces by hydrogen/deuterium exchange mass spectrometry.

Authors:  Bo Zhou; Jialin Zhang; Sijiu Liu; Sharanya Reddy; Fang Wang; Zhong-Yin Zhang
Journal:  J Biol Chem       Date:  2006-10-17       Impact factor: 5.157

Review 4.  Dual specificity phosphatases: a gene family for control of MAP kinase function.

Authors:  M Camps; A Nichols; S Arkinstall
Journal:  FASEB J       Date:  2000-01       Impact factor: 5.191

5.  The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice.

Authors:  O F Bueno; L J De Windt; K M Tymitz; S A Witt; T R Kimball; R Klevitsky; T E Hewett; S P Jones; D J Lefer; C F Peng; R N Kitsis; J D Molkentin
Journal:  EMBO J       Date:  2000-12-01       Impact factor: 11.598

6.  Mechanism of mitogen-activated protein kinase phosphatase-3 activation by ERK2.

Authors:  B Zhou; Z Y Zhang
Journal:  J Biol Chem       Date:  1999-12-10       Impact factor: 5.157

7.  Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice.

Authors:  G Pagès; S Guérin; D Grall; F Bonino; A Smith; F Anjuere; P Auberger; J Pouysségur
Journal:  Science       Date:  1999-11-12       Impact factor: 47.728

Review 8.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.

Authors:  P J Roberts; C J Der
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

9.  Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo.

Authors:  Nicole H Purcell; Benjamin J Wilkins; Allen York; Marc K Saba-El-Leil; Sylvain Meloche; Jeffrey Robbins; Jeffery D Molkentin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-20       Impact factor: 11.205

10.  Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure.

Authors:  Hiroyuki Nakayama; Xiongwen Chen; Christopher P Baines; Raisa Klevitsky; Xiaoying Zhang; Hongyu Zhang; Naser Jaleel; Balvin H L Chua; Timothy E Hewett; Jeffrey Robbins; Steven R Houser; Jeffery D Molkentin
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

View more
  85 in total

1.  Mechanisms of regulation of oligodendrocyte development by p38 mitogen-activated protein kinase.

Authors:  Li-Jin Chew; William Coley; Ying Cheng; Vittorio Gallo
Journal:  J Neurosci       Date:  2010-08-18       Impact factor: 6.167

2.  DUSP6 Inhibitor (E/Z)-BCI Hydrochloride Attenuates Lipopolysaccharide-Induced Inflammatory Responses in Murine Macrophage Cells via Activating the Nrf2 Signaling Axis and Inhibiting the NF-κB Pathway.

Authors:  Fan Zhang; Bufu Tang; Zijiao Zhang; Di Xu; Guowu Ma
Journal:  Inflammation       Date:  2019-04       Impact factor: 4.092

Review 3.  Heart genetics in a small package, exploiting the condensed genome of Ciona intestinalis.

Authors:  Christina D Cota; Fernando Segade; Brad Davidson
Journal:  Brief Funct Genomics       Date:  2013-09-04       Impact factor: 4.241

4.  Cardiomyocyte proliferation prevents failure in pressure overload but not volume overload.

Authors:  Karl Toischer; Wuqiang Zhu; Mark Hünlich; Belal A Mohamed; Sara Khadjeh; Sean P Reuter; Katrin Schäfer; Deepak Ramanujam; Stefan Engelhardt; Loren J Field; Gerd Hasenfuss
Journal:  J Clin Invest       Date:  2017-10-30       Impact factor: 14.808

Review 5.  Cardiac muscle regeneration: lessons from development.

Authors:  Mark Mercola; Pilar Ruiz-Lozano; Michael D Schneider
Journal:  Genes Dev       Date:  2011-02-15       Impact factor: 11.361

Review 6.  Regulation of cardiac hypertrophy and remodeling through the dual-specificity MAPK phosphatases (DUSPs).

Authors:  Ruijie Liu; Jeffery D Molkentin
Journal:  J Mol Cell Cardiol       Date:  2016-08-27       Impact factor: 5.000

7.  Dusp6 is a genetic modifier of growth through enhanced ERK activity.

Authors:  Andy H Vo; Kayleigh A Swaggart; Anna Woo; Quan Q Gao; Alexis R Demonbreun; Katherine S Fallon; Mattia Quattrocelli; Michele Hadhazy; Patrick G T Page; Zugen Chen; Ascia Eskin; Kevin Squire; Stanley F Nelson; Elizabeth M McNally
Journal:  Hum Mol Genet       Date:  2019-01-15       Impact factor: 6.150

8.  TLR4 signaling in effector CD4+ T cells regulates TCR activation and experimental colitis in mice.

Authors:  José M González-Navajas; Sean Fine; Jason Law; Sandip K Datta; Kim P Nguyen; Mandy Yu; Maripat Corr; Kyoko Katakura; Lars Eckman; Jongdae Lee; Eyal Raz
Journal:  J Clin Invest       Date:  2010-01-04       Impact factor: 14.808

9.  Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages.

Authors:  Gabriela Molina; Andreas Vogt; Ahmet Bakan; Weixiang Dai; Pierre Queiroz de Oliveira; Wade Znosko; Thomas E Smithgall; Ivet Bahar; John S Lazo; Billy W Day; Michael Tsang
Journal:  Nat Chem Biol       Date:  2009-07-05       Impact factor: 15.040

10.  Heart-specific deletion of CnB1 reveals multiple mechanisms whereby calcineurin regulates cardiac growth and function.

Authors:  Marjorie Maillet; Jennifer Davis; Mannix Auger-Messier; Allen York; Hanna Osinska; Jérôme Piquereau; John N Lorenz; Jeffrey Robbins; Renée Ventura-Clapier; Jeffery D Molkentin
Journal:  J Biol Chem       Date:  2009-12-27       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.